Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gene targeting in vivo with pegylated immunoliposomes.

× No keyword cloud information.

17 in total

Review 1. shRNA and siRNA delivery to the brain.

Authors: William M Pardridge
Journal: Adv Drug Deliv Rev Date: 2007-03-16 Impact factor: 15.470

2. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors: Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal: Nanomedicine Date: 2008-08-08 Impact factor: 5.307

Review 3. Gene-based therapies in Parkinson's disease.

Authors: Patricia J Allen; Andrew Feigin
Journal: Neurotherapeutics Date: 2014-01 Impact factor: 7.620

4. Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation.

Authors: Chun Chu; Yun Zhang; Ruben J Boado; William M Pardridge
Journal: Pharm Res Date: 2006-06-21 Impact factor: 4.200

5. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy.

Authors: Yun Zhang; William M Pardridge
Journal: Pharm Res Date: 2008-12-23 Impact factor: 4.200

6. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus.

Authors: Yogesh Scindia; Umesh Deshmukh; Pushpa-Rekha Thimmalapura; Harini Bagavant
Journal: Arthritis Rheum Date: 2008-12

Gene targeting in vivo with pegylated immunoliposomes.

Review 1. shRNA and siRNA delivery to the brain.

2. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Review 3. Gene-based therapies in Parkinson's disease.

4. Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation.

5. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy.

6. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus.

Review 7. Blood-brain barrier transport of non-viral gene and RNAi therapeutics.

8. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses.

9. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer.

Review 10. Focusing brain therapeutic interventions in space and time for Parkinson's disease.